'

What Do Doctors Think About Biosimilars?

Понравилась презентация – покажи это...





Слайд 0

What Do Doctors Think About Biosimilars? Powered by Small World Social www.biolink.us


Слайд 1

In March 2015, the Alliance for Safe Biologic Medicines (ASBM), released results from their survey of 400 US physicians on biologics medicines labeling. Powered by Small World Social www.biolink.us


Слайд 2

The web-based survey was conducted before the FDA approved Zarxio, the first biosimilar in the US, and sought the view of dermatologists, endocrinologists, oncologists, nephrologists, neurologists and rheumatologists. It found… Powered by Small World Social www.biolink.us


Слайд 3

Powered by Small World Social considered it important for a biosimilar’s product label to clearly indicate that it is a biosimilar. 90% of correspondents 4 Biolink.us


Слайд 4

Powered by Small World Social it important for the biosimilar label to include the biosimilar sponsor’s analytical data demonstrating its analytical similarity to the reference product 82% thought 5 Biolink.us


Слайд 5

Powered by Small World Social It important that the biosimilar label includes the clinical data, if any, submitted to the FDA by the sponsor again demonstrating that it is highly similar to the reference product 83% thought 6 Biolink.us


Слайд 6

Powered by Small World Social It important that the label explicitly state that the specific indications or conditions of use approved for the originator product that are not approved for the biosimilar product 79% found 7 Biolink.us


Слайд 7

In 2013, the ASBM also surveyed 470 European physicians, from the United Kingdom, France, Germany, Italy and Spain to gauge their views on non-proprietary naming of biological medicines. Powered by Small World Social www.biolink.us


Слайд 8

The survey highlighted the lack of awareness about biosimilars amongst prescribing specialist physicians and the need for further education. It found… Powered by Small World Social www.biolink.us


Слайд 9

Powered by Small World Social said they are ‘familiar’ with biosimilars, but only have a basic understanding 54% of respondents 10 Biolink.us


Слайд 10

Powered by Small World Social were unable to define biosimilars 20% of the physicians 11 Biolink.us


Слайд 11

Powered by Small World Social had never heard of biosimilars 4% of respondents 12 Biolink.us


Слайд 12

Powered by Small World Social were ‘very familiar’, with a complete understanding of biosimilars 22% of the physicians 13 Biolink.us


Слайд 13

Meanwhile, a study conducted by the Tufts Center of the Study of Drug Development, at Tufts University in Boston, found that… Powered by Small World Social www.biolink.us


Слайд 14

Powered by Small World Social While the majority of physicians, 70%, surveyed said they would be likely to prescribe biosimilars to a new patient, the overall lack of familiarity with the new products among specialist physicians could slow the uptake of biosimilars in the U.S. 15 Biolink.us


Слайд 15

Powered by Small World Social www.biolink.us Want to read more about biosimilars? Visit: https://www.smallworldsocial.com/biolink/ to get the latest in biosimilar news curated from around the world


×

HTML:





Ссылка: